These data suggest that GLP-1R agonism attenuates atherosclerosis formation and vascular immune cell activation most likely by reducing systemic inflammation independently of changes in lipid and glucose metabolism
Phase I and II clinical trials conducted have shown improved cognitive and motor function with different drugs from GLP-1RA group although the small sized and limited duration of trials have not provided a conclusive result to influence the practice, although with further advancement in ongoing trials effects observed may be noteworthy for intervention in future practice (119)
Still, compounded versions gained traction in 2022 when there were shortages of the drugs, and they are still going strong for a few main reasons: Some people encounter some pretty rough side effects like nausea and diarrhea, so microdosing can be a way to avoid those issues while still reaping some benefits
Yes, a GLP-1 agonist may temporarily get you there, but its not going to keep you there
Kinlen D, Cody D, OShea D
For a tailored weight loss plan including a vital blood test, consider the SheMed Weight Loss Programme